KPV: the alpha-MSH-derived tripeptide studied for gut inflammation

KPV is a tripeptide of lysine, proline, and valine corresponding to the C-terminal fragment of alpha-MSH, the 13-amino-acid melanocortin hormone derived from POMC. it concentrates the anti-inflammatory motif of alpha-MSH while minimizing the pigment-related signaling. its small size and PepT1-mediated transport into intestinal epithelial and immune cells are the mechanistic basis for an unusually coherent oral gut-targeting story, but the evidence base for human disease remains preclinical.

what is KPV?

KPV is the alpha-MSH C-terminal tripeptide Lys-Pro-Val, also written as alpha-MSH(11-13). it was developed as a minimal-sequence strategy to keep alpha-MSH's anti-inflammatory effects while shedding the pigment and melanotropic signaling associated with the full-length hormone.

alpha-MSH is one of the peptide products of proopiomelanocortin (POMC) processing, and it has broad anti-inflammatory effects across skin, gut, central nervous system, airway, and arthritis-related models [1]. the practical problem is that melanocortin receptor agonism, especially at MC1R, also drives pigmentation, which is a real clinical liability in many target indications. researchers therefore mapped where the anti-inflammatory motif sat within alpha-MSH and converged on the C-terminal three residues, KPV, as the smallest fragment that retained the anti-inflammatory phenotype in multiple models.

the small size has two pharmacology consequences worth knowing. on the negative side, tripeptides are short, generally lack stable tertiary structure, and are vulnerable to enzymatic degradation; KPV-specific stability-indicating HPLC work confirms degradation under acid, alkali, and oxidative stress. on the positive side, tripeptides like KPV are substrates of PepT1, a di- and tripeptide transporter expressed on intestinal epithelial and immune cells, which gives KPV an active transport route into inflamed gut tissue that most larger peptides do not have [2].

how does it work?

in inflammation models KPV reduces NF-kB pathway activation, lowers pro-inflammatory cytokines like TNF-alpha, IL-1beta, and IL-6, and reduces inflammatory cell infiltration. it also engages PepT1 transport in the gut, which delivers it intracellularly in epithelial and immune cells. it can act independently of canonical melanocortin receptor signaling in several models.

the core anti-inflammatory signaling story is consistent across systems. KPV reduces NF-kB activity and nuclear signaling in inflammatory models [2], and that reduction is reflected downstream as lower TNF-alpha, IL-1beta, and IL-6 output and as lower myeloperoxidase and inflammatory-cell infiltration in colitis and peritonitis-like settings [3]. the NF-kB connection is the cleanest molecular handle the literature offers for why KPV behaves the way it does in disease models.

the receptor-biology story is more complicated and is one of the most interesting teaching points on this page. KPV often retains anti-inflammatory activity in settings where canonical MC1R signaling is non-functional, and some cell models show weak or absent cAMP responses, suggesting that at least part of the effect is melanocortin-receptor-independent [1]. other cell models show calcium-linked signaling and context-dependent receptor interactions, so the mechanism is likely mixed and tissue-specific rather than a single clean pathway.

the PepT1 story is what makes KPV unusual among anti-inflammatory peptides. Dalmasso and colleagues showed in 2008 that KPV is taken up via PepT1 on intestinal epithelial and immune cells, and that this uptake is linked to its anti-inflammatory effects [2]. PepT1 is upregulated in inflamed intestinal tissue, which turns an inflammation context into a selective delivery opportunity, the opposite of how most systemic drugs behave.

what does the evidence show?

KPV's strongest evidence base is in preclinical models of inflammatory bowel disease, including DSS colitis, TNBS colitis, and T-cell transfer colitis. nanoparticle and hydrogel oral delivery systems have extended those results with colon-selective release. human efficacy trials in IBD have not been established and the substance is not approved for any indication.

the IBD preclinical program is the strongest single body of work on KPV. Dalmasso and colleagues reported that oral KPV improved DSS and TNBS colitis outcomes in mice with reduced inflammatory signaling and improved histology [2]. Kannengiesser and colleagues independently showed that KPV improved DSS and T-cell transfer colitis with reduced myeloperoxidase, fewer infiltrates, and better recovery [3]. Laroui and colleagues then showed that KPV-loaded nanoparticles in an alginate-chitosan hydrogel improved DSS colitis with colon-selective release behavior [4], and Sun and colleagues showed that hyaluronic-acid-functionalized KPV nanoparticles achieved better epithelial and macrophage targeting with improved mucosal healing and TNF-alpha reduction [5].

the colitis-associated cancer extension is also worth knowing. Wang and colleagues reported that KPV reduced tumor multiplicity and inflammatory signaling in mouse colitis-associated cancer paradigms, with PepT1-linked mechanism [6]. that is mechanistically interesting because it tracks the same transporter-driven story into a tumor-promotion endpoint rather than only an inflammation endpoint.

outside the gut, the evidence is thinner. historical alpha-MSH(11-13) work shows suppression of acute inflammation and contact-sensitivity responses in skin models, and KPV has demonstrated transdermal feasibility in human skin only with delivery enhancement (microneedles or iontophoresis), so topical use is technically possible but pharmacologically demanding. for arthritis and neuroinflammation, most of the supportive data are at the alpha-MSH(11-13) level rather than at the direct KPV-disease-trial level, and that distinction should be respected when reading marketing copy that conflates them.

regulatory status

KPV is not FDA approved as a drug for any indication. it appears in the FDA's list of certain compounded bulk substances that may present significant safety risks under section 503A (Category 2), with the agency noting insufficient human safety information. a public clinical-trials registry search did not identify established interventional efficacy trials specifically for KPV.

the FDA position is the most important regulatory fact on this page. KPV is listed in the agency's Category 2 bulk-substances safety-risk context, alongside other unapproved peptides like AOD-9604 and MOTS-c. that placement does not mean approval is pending; it means the agency has flagged the substance as one for which the human exposure data and safety information are inadequate to determine the risk-benefit profile [7]. Category 2 placement is not an approval pathway.

the market activity for KPV is therefore largely research-use and compounding-policy dependent rather than approved-therapy status. peptide-vendor protocols and community dose ranges that circulate online do not derive from FDA-cleared dose-finding work and do not have the quality-control framework that approved drugs operate under. product purity, identity, and endotoxin testing vary substantially across grey-market vendors.

safety and what is unknown

preclinical and cell-line work has generally reported anti-inflammatory effects without major overt toxicity in study windows, but this does not establish human safety. the FDA Category 2 listing specifically notes the absence of an identified human exposure dataset sufficient to characterize harm. long-term, multi-year human safety data for KPV do not exist.

the published preclinical and cell-biology safety signal across animal studies is broadly favorable in short windows. intestinal-cell biocompatibility has been reported in hyaluronic-acid-functionalized KPV nanoparticle work, and disease models have not raised obvious toxicity flags [5]. the practical caveat is that "few reported severe effects in preclinical literature" is not the same as established human safety, and the FDA listing makes that distinction explicit.

non-clinical risk domains that any beginner should be aware of include product-quality variability in grey-market sources, the absence of standardized handling and shelf-life data outside specialized labs, and the absence of validated human dose-finding work. these are not unique to KPV but they are particularly relevant because KPV is often discussed as orally usable in community settings, and oral use does not bypass the underlying quality and exposure-data gaps.

where it fits in peptide therapy

KPV sits inside the alpha-MSH and melanocortin family and is the canonical minimal anti-inflammatory tripeptide. its most distinctive feature is the PepT1-mediated oral gut-targeting platform, which is uncommon in peptide pharmacology. it is closely related to KdPT and to the (CKPV)2 dimer, both of which appear in the same anti-inflammatory tripeptide conversation.

relative to full-length alpha-MSH (1-13), KPV shares the anti-inflammatory phenotype while shedding much of the melanocortin-receptor agonism and pigment-related signaling that complicate full-length alpha-MSH for many indications. the tradeoff is that KPV has less mature clinical evidence than any approved IBD therapy, and "less pigment baggage" does not by itself substitute for a controlled efficacy trial.

relative to related tripeptide derivatives, KdPT has strong anti-inflammatory and non-pigment findings in intestinal and psoriasis-like models and is often used as a comparator platform, and (CKPV)2, a dimeric analog, has shown comparable or better potency than KPV in some endotoxin and inflammation studies. for adjacent anti-inflammatory and tissue-repair peptide biology, the GI repair angle continues in BPC-157; for melanocortin-receptor biology in a pigment and appetite context the canonical comparator is melanotan 2; and the foundational anti-inflammatory pathway story is covered in our free how peptides work module.